Literature DB >> 25726423

Ribosomal protein L3 mutations are associated with cfr-mediated linezolid resistance in clinical isolates of Staphylococcus cohnii.

Hongtao Xu1, Rui Tian, Yanming Li, Dongke Chen, Yalin Liu, Yunjian Hu, Fei Xiao.   

Abstract

From June, 2012 to November, 2013 five linezolid-resistant Staphylococcus cohnii isolates were identified in our hospital in Beijing, China. The investigation of the resistance mechanisms confirmed that the cfr-carrying plasmids were the main cause of linezolid resistance in those clinical isolates. Moreover, all the five isolates had ribosomal protein L3 mutations, which had different coordinate effect on cfr-mediated linezolid resistance directly through the substitution of serine 158 by phenylalanine or tyrosine in L3 protein. In this study, two types of plasmids (p432, p438) (Accession No. KM114207) were found, which share high sequence identity with previously reported cfr-carrying pRM01 and pMHZ plasmids originated from northern and southern China, showing wide regional dissemination in China. The stability of linezolid resistance was studied by passaging single colonies serially on antibiotic-free blood medium, which showed that the susceptible derivatives emerged until the passages 39-42 with the elimination of cfr-carrying plasmid. Thus the high stability of this plasmid may pose a risk for the transmission among patients or even cause an outbreak in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25726423     DOI: 10.1007/s00284-015-0793-y

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  12 in total

1.  The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics.

Authors:  Katherine S Long; Jacob Poehlsgaard; Corinna Kehrenberg; Stefan Schwarz; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  Distribution of the multidrug resistance gene cfr in Staphylococcus species isolates from swine farms in China.

Authors:  Yang Wang; Wanjiang Zhang; Juan Wang; Congming Wu; Zhangqi Shen; Xiao Fu; Yang Yan; Qijing Zhang; Stefan Schwarz; Jianzhong Shen
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

3.  Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.

Authors:  Hongbin Chen; Weiyuan Wu; Ming Ni; Yingmei Liu; Jixia Zhang; Fei Xia; Wenqiang He; Qi Wang; Zhanwei Wang; Bin Cao; Hui Wang
Journal:  Int J Antimicrob Agents       Date:  2013-07-20       Impact factor: 5.283

4.  Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.

Authors:  Jeffrey B Locke; Gracia Morales; Mark Hilgers; Kedar G C; Shahad Rahawi; Juan José Picazo; Karen Joy Shaw; Jeffrey L Stein
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

5.  Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; David J Farrell; Teresa Spanu; Giovanni Fadda; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2010-09-14       Impact factor: 5.790

6.  Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010).

Authors:  Chunjiang Zhao; Hongli Sun; Hui Wang; Yudong Liu; Bijie Hu; Yunsong Yu; Ziyong Sun; Yunzhuo Chu; Bin Cao; Kang Liao; Jin'e Lei; Zhidong Hu; Liyan Zhang; Xiaobing Zhang; Yingchun Xu; Zhanwei Wang; Minjun Chen
Journal:  Diagn Microbiol Infect Dis       Date:  2012-04-21       Impact factor: 2.803

7.  Emergence of cfr-harbouring coagulase-negative staphylococci among patients receiving linezolid therapy in two hospitals in China.

Authors:  Xue-Jing Yang; Yan Chen; Qing Yang; Ting-Ting Qu; Li-Lin Liu; Hai-Ping Wang; Yun-Song Yu
Journal:  J Med Microbiol       Date:  2013-02-28       Impact factor: 2.472

8.  Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid.

Authors:  Seok-Ming Toh; Liqun Xiong; Cesar A Arias; Maria V Villegas; Karen Lolans; John Quinn; Alexander S Mankin
Journal:  Mol Microbiol       Date:  2007-06       Impact factor: 3.501

9.  The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning.

Authors:  Daniel N Wilson; Frank Schluenzen; Joerg M Harms; Agata L Starosta; Sean R Connell; Paola Fucini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

10.  Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center.

Authors:  Keith Miller; Colin J Dunsmore; Colin W G Fishwick; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

View more
  3 in total

1.  Combined Effect of the Cfr Methyltransferase and Ribosomal Protein L3 Mutations on Resistance to Ribosome-Targeting Antibiotics.

Authors:  Kevin K Pakula; Lykke H Hansen; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Different Resistance Mechanisms for Cadazolid and Linezolid in Clostridium difficile Found by Whole-Genome Sequencing Analysis.

Authors:  Patrick Caspers; Hans H Locher; Philippe Pfaff; Sarah Diggelmann; Georg Rueedi; Daniel Bur; Daniel Ritz
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 3.  Staphylococcus aureus Nasal Carriage and Autoimmune Diseases: From Pathogenic Mechanisms to Disease Susceptibility and Phenotype.

Authors:  Fulvia Ceccarelli; Carlo Perricone; Giulio Olivieri; Enrica Cipriano; Francesca Romana Spinelli; Guido Valesini; Fabrizio Conti
Journal:  Int J Mol Sci       Date:  2019-11-11       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.